Filip Krag Knop

Filip Krag Knop

Clinical Professor

Member of:

  • Internal Medicine: Endocrinology


Publication year:
All
11 - 17 out of 17Page size: 10
Sort by: Title
  1. Published

    Incretin-based therapy and type 2 diabetes

    Hare, K. J. & Knop, Filip Krag, 1 Jan 2010, In: Vitamins and Hormones. 84, p. 389-413 25 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  2. Published

    Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?

    Christensen, M. & Knop, Filip Krag, 1 Apr 2010, In: Current Diabetes Reports. 10, 2, p. 124-32 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects

    Hansen, K. B., Vilsbøll, Tina, Bagger, J. I., Holst, Jens Juul & Knop, Filip Krag, 1 Jul 2010, In: The Journal of clinical endocrinology and metabolism. 95, 7, p. 3309-17 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

    Hare, K. J., Vilsbøll, Tina, Asmar, M., Deacon, Carolyn F., Knop, Filip Krag & Holst, Jens Juul, 1 Jul 2010, In: Diabetes. 59, 7, p. 1765-70 6 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiency

    Knop, Filip Krag, Vilsbøll, Tina, Lund, A., Krarup, T., Holst, Jens Juul & Hornum, Mads, 6 Sep 2010, In: Journal of the Pancreas. 11, 5, p. 489-91 3 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus

    Aaboe, K., Knop, Filip Krag, Vilsbøll, T., Deacon, Carolyn F., Holst, Jens Juul, Madsbad, S. & Krarup, T. M., 1 Apr 2010, In: Diabetes, Obesity and Metabolism. 12, 4, p. 323-33 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose- and non-glucose-induced insulin secretion in patients with type 2 diabetes mellitus

    Aaboe, K., Knop, Filip Krag, Vilsbøll, Tina, Deacon, Carolyn F., Holst, Jens Juul, Madsbad, Sten & Krarup, T., 2010, In: Diabetes, Obesity and Metabolism. 12, 4, p. 323-333 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1 2 Next

ID: 40100368